In a recent press release, Catalent and BrainStorm Cell Therapeutics Inc. (“BrainStorm”) announced a partnership to manufacture NurOwn for patients with amyotrophic lateral sclerosis (ALS).
CHAMP1 Research Foundation
The CHAMP1 Foundation is an organization created for parents of children with developmental delay, hypotonia, cerebral palsy, autism, and epilepsy among many other diagnoses a result of a change in the CHAMP1 gene.
Our vision is to find effective treatments and a cure for CHAMP1 disorders.
Our mission is to improve the lives of those affected by CHAMP1 disorders through clinical research, effective treatments, public awareness, early detection, family support and patient advocacy.
Our Goals: To coordinate and collaborate with the global scientific community to understand the function of the CHAMP1 gene in order to accelerate the develop of effective treatments and a cure for CHAMP1 disorders.
To increase the medical community and public awareness of the complexity and potential severity of CHAMP1 disorders.
To provide educational and emotional support for those affected by CHAMP1 disorders.
Condition Awareness & Advocacy
Here is a list of conditions this partner raises awareness and advocacy for:
Connect With the CHAMP1 Foundation
Patient Worthy Posts on CHAMP1 Disorders will be Coming Soon!
Growing up without a diagnosis is hard. In a world which frequents new scientific discoveries, you’re still living as a medical mystery. When no one
Takeda Pharmaceuticals has recently announced the results from their open-label extension study, titled VISIBLE, which evaluates Entyvio as a treatment for ulcerative colitis. According to
Scientists are investigating whether delaying the onset of epilepsy in very young children could reduce or prevent other neurological conditions such as learning difficulties and
The World Alliance of Pituitary Organizations unites the pituitary patient community and as one of our partners, they sent us their latest newsletter! In it, you
Nontuberculous mycobacterial (NTM) lung infection occurs when someone inhales nontuberculous mycobacteria from the environment. There are various types of this bacteria, giving NTM different forms. But